ReviewMolecular neurobiology2013
Non-coding RNAs in Alzheimer's disease.
Review in Molecular neurobiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 1 synthesis or guideline pooled it, 168 citations in OpenAlex.
- Non-coding RNAs and Mitochondrial Dysfunction in Alzheimer's Disease: A Systematic Review.Molecular neurobiology · 2026Pooled it
- Trial
- Epigenetic Editing in Neurological and Neuropsychiatric Disorders: Pioneering Next-Gen Therapeutics for Precision Gene Control.Molecular neurobiology · 2025Review
- Targeting of PP2 A/GSK3β/PTEN Axis in Alzheimer Disease: The Mooting Evidence, Divine, and Devil.Cellular and molecular neurobiology · 2025Review
- miR-92a-3p and miR-320a are Upregulated in Plasma Neuron-Derived Extracellular Vesicles of Patients with Frontotemporal Dementia.Molecular neurobiology · 2025Article
- A nested case-control study of circular ribonucleic acid expression profiles in the peripheral blood of pregnant women with pre-eclampsia.Pakistan journal of medical sciences · 2024Article
- Identification of pathological pathways centered on circRNA dysregulation in association with irreversible progression of Alzheimer's disease.Genome medicine · 2024Article
- The roles of long non-coding RNAs in Alzheimer's disease diagnosis, treatment, and their involvement in Alzheimer's disease immune responses.Non-coding RNA research · 2024Review
- Review
- Article
- Can salivary and skin microbiome become a biodetector for aging-associated diseases? Current insights and future perspectives.Frontiers in aging · 2024Review
- Optimal decision-making in high-throughput virtual screening pipelines.Patterns (New York, N.Y.) · 2023Article
- Can Genetic Markers Predict the Sporadic Form of Alzheimer's Disease? An Updated Review on Genetic Peripheral Markers.International journal of molecular sciences · 2023Review
- Long noncoding RNA HIKER regulates erythropoiesis in Monge's disease via CSNK2B.The Journal of clinical investigation · 2023Article
- The Role of miR-128 in Neurodegenerative Diseases.International journal of molecular sciences · 2023Review
- Augmentation of 2-arachidonoylglycerol signaling in astrocytes maintains synaptic functionality by regulation of miRNA-30b.Experimental neurology · 2023Article
- A Candidate microRNA Profile for Early Diagnosis of Sporadic Alzheimer's Disease.Journal of Alzheimer's disease reports · 2023Article
- Predicting potential lncRNA biomarkers for lung cancer and neuroblastoma based on an ensemble of a deep neural network and LightGBM.Frontiers in genetics · 2023Article
- Role of miRNAs in Neurodegeneration: From Disease Cause to Tools of Biomarker Discovery and Therapeutics.Genes · 2022Review
- PRIP: A Protein-RNA Interface Predictor Based on Semantics of Sequences.Life (Basel, Switzerland) · 2022Article
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a complex neurodegenerative disorder and the most common dementia among the elderly. Accumulating research indicates that noncoding RNAs (ncRNAs), especially microRNAs (miRNAs) and long noncoding RNAs (lncRNAs), are increasingly being implicated in AD. MiRNAs are conserved small ncRNAs that control gene expression post-transcriptionally while lncRNAs function in many ways. Recent profiling research in human or mouse models suggests that miRNAs are aberrantly expressed in AD, and these have been implicated in the regulation of amyloid-β (Aβ) peptide, tau, inflammation, cell death, and other aspects which are the main pathomechanisms of AD. In addition, regulation of miRNAs varies in blood, and cerebral spinal fluid may indicate alterations in AD. Together with brain-specific miRNAs, these miRNAs could be potential AD biomarkers. All the above may provide the basis for new approaches for AD. Here, we review current findings regarding ncRNA research in human and mouse models to provide a strong basis for future study aiming at promising contributions of ncRNA in AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.